has been cited by the following article(s):
[1]
|
Long-Acting Lipoglycopeptide Antibiotics (Dalbavancin and Oritavancin) for the Treatment of Endotipsitis in a Patient With Cirrhosis
Infectious Diseases in Clinical Practice,
2022
DOI:10.1097/IPC.0000000000001082
|
|
|
[2]
|
Long-Acting Lipoglycopeptide Antibiotics (Dalbavancin and Oritavancin) for the Treatment of Endotipsitis in a Patient With Cirrhosis
Infectious Diseases in Clinical Practice,
2022
DOI:10.1097/IPC.0000000000001082
|
|
|
[3]
|
Long-Acting Lipoglycopeptide Antibiotics (Dalbavancin and Oritavancin) for the Treatment of Endotipsitis in a Patient With Cirrhosis
Infectious Diseases in Clinical Practice,
2022
DOI:10.1097/IPC.0000000000001082
|
|
|